VALENCIA, California, April 30, 2026
SetPoint Medical announced the first patients enrolled in a pilot clinical study evaluating its neuroimmune modulation device, the SetPoint System®, for relapsing-remitting multiple sclerosis (RRMS). The first-of-its-kind investigational study aims to determine whether targeted vagus nerve stimulation can promote remyelination, addressing one of the most critical unmet needs in multiple sclerosis treatment. The study is being conducted under an Investigational Device Exemption (IDE) from the U.S. FDA, and the device has already received Breakthrough Device Designation and acceptance into the Total Product Life Cycle Advisory Program (TAP), signaling strong regulatory support for this innovative therapeutic approach.
Novel Neuroimmune Approach Targets Remyelination
Unlike current therapies that primarily focus on reducing inflammation, SetPoint Medical’s approach targets the underlying neuroimmune pathways to potentially restore damaged nerve insulation. The SetPoint System® is a miniaturized implantable neurostimulator placed on the vagus nerve, delivering controlled electrical stimulation for one minute daily. This stimulation is designed to activate the body’s innate anti-inflammatory mechanisms while creating conditions that may support myelin repair, a process known as remyelination.
By addressing both immune dysfunction and nerve repair, the technology represents a paradigm shift from symptom management to potential disease modification and neural recovery in multiple sclerosis.
Rigorous Clinical Study Design Across Leading Centers
Advertisement
The multicenter, randomized, double-blind, sham-controlled pilot study will enroll up to 60 patients across the United States, evaluating the device as an adjunct to standard disease-modifying therapies (DMTs). Primary outcomes will focus on safety and remyelination effects over a one-year period. The trial is being conducted at leading institutions, including Shepherd Center in Atlanta, UW Medicine in Seattle, Johns Hopkins University, and University of Texas Health Science Center, among others. This robust design ensures high-quality clinical data to assess both the therapeutic potential and safety profile of neuroimmune modulation in MS patients.
Expanding the Role of Device-Based Therapies in Autoimmune Diseases
Multiple sclerosis affects nearly one million people in the United States, causing progressive neurological damage due to the loss of the myelin sheath that protects nerve fibers. Current treatments slow disease progression but do not effectively restore damaged myelin, leaving a significant gap in long-term care.
SetPoint Medical’s technology builds on its FDA-approved use in rheumatoid arthritis, where neuroimmune modulation has demonstrated the ability to reduce inflammation through vagus nerve activation. Extending this platform to MS represents a strategic move to expand device-based therapies into broader autoimmune and neurological conditions, including Crohn’s disease.
This study marks an important step toward validating bioelectronic medicine as a viable therapeutic category, combining neuroscience, immunology, and medical device innovation. If successful, the SetPoint System could redefine MS treatment by enabling functional nerve repair alongside immune regulation, potentially improving long-term outcomes and reducing disability progression.
Source: SetPoint Medical press release
